Assess whether pediatric studies are necessary or waivable (214b92)

Situation

Pharmacovigilance work in a mid-size sponsor after a complete response letter now turns on pediatric studies are necessary because a pediatric ethicist objecting to the proposed design put disproportionate reporting signal workbook in play. CMC change-control owner should say what disproportionate reporting signal workbook proves.

Decision

CMC change-control owner in a mid-size sponsor after a complete response letter must choose Pediatric studies are necessary / Waivable using disproportionate reporting signal workbook after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• A pediatric ethicist objecting to the proposed design is noise around an already-controlled Pharmacovigilance process in a mid-size sponsor after a complete response letter, given disproportionate reporting signal workbook.
• A pediatric ethicist objecting to the proposed design is the event in disproportionate reporting signal workbook that forces Pediatric studies are necessary for CMC change-control owner under Pharma & Life Sciences.
• Disproportionate reporting signal workbook shows a one-file miss after a pediatric ethicist objecting to the proposed design, not a Pharmacovigilance program failure.
• Disproportionate reporting signal workbook cannot decide pediatric studies are necessary yet after a pediatric ethicist objecting to the proposed design; hold is the only Pharma & Life Sciences close a mid-size sponsor after a complete response letter can defend.

Analysis required

• Check whether disproportionate reporting signal workbook supports the labeled claim CMC change-control owner would keep.
• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a pediatric ethicist objecting to the proposed design.
• For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against a pediatric ethicist objecting to the proposed design and write the one fact that would move pediatric studies are necessary for CMC change-control owner.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / Pharmacovigilance packet (disproportionate reporting signal workbook after a pediatric ethicist objecting to the proposed design). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after a pediatric ethicist objecting to the proposed design, then the two facts that force it, then the Monday action for CMC change-control owner in a mid-size sponsor after a complete response letter.